[Clinical efficacy of myocardial cytoprotector trimetazidine in peri- and postmenopausal women with ischemic heart disease].

Efficacy of 3-12 month use of trimetazidine hydrochloride combined with verapamil was assessed in postmenopausal women with effort angina by repetitive exercise tests, ECG monitoring and echocardiography. The use of trimetazidine was associated with augmentation of antianginal and antiischemic action of verapamil, improvement of systolic and diastolic left ventricular function, decrease in frequency of hospitalizations because of exacerbation of ischemic heart disease. These effects were evident in all age groups throughout the period of observation and did not depend on the ischemic heart disease duration.

[Piracetam and tocopherol acetate ability to potentiate clinical effect of antianginal drugs in presenile and senile patients with ischemic heart disease (unstable angina)].

Potentiating ability of piracetam and tocopherol acetate was studied outpatiently in aged patients with ischemic heart disease. It was found that the addition of piracetam and tocopherol acetate to conventional antianginal drug therapy brings higher response and exercise tolerance, contributes to more effective hemodynamic and energetic support of the exercise, to positive changes in the central and peripheral hemodynamics.

[The clinical, hemodynamic and hormonal-metabolic effects of the calcium-antagonist treatment of middle-aged and elderly patients with IHD at the polyclinic stage of rehabilitation].

160 presenile and senile CHD patients received calcium antagonists nifedipine, verapamil, diltiazem. The highest antianginal effect occurred after a course of verapamil with special effect in those functionally compromised. Rheoencephalographic picture was dependent on the initial functional class of the patient and overall treatment efficacy.

[Clinical and hemodynamic effect of piracetam (Nootropil) in elderly and very old patients with coronary heart disease in the outpatient rehabilitative period].

The clinical and hemodynamic efficiency of piracetam (nootporil) used in the long-term combined therapy of elderly and senile patients with chronic coronary heart diseases was studied outpatiently. This drug led to a significant enhancement of the antianginal effect of the basic treatment, to more regression of clinical signs of chronic circulatory insufficiency, to positive central hemodynamic changes, higher exercise tolerance, lower energy consumption index per performance unit, increased adaptive potential of the circulatory system, and maintained optimal cerebral blood flow.